CN Patent

CN114007600A — 与神经系统病症的治疗响应有关的遗传变异

Assigned to Vistagen Therapeutics Inc · Expires 2022-02-01 · 4y expired

What this patent protects

描述了治疗抑郁症、重性抑郁症、自杀意念和相关病症的方法，通过基于受试者的基因型向受试者施用L‑4‑氯犬尿氨酸(L‑4‑Cl‑KYN)。

USPTO Abstract

描述了治疗抑郁症、重性抑郁症、自杀意念和相关病症的方法，通过基于受试者的基因型向受试者施用L‑4‑氯犬尿氨酸(L‑4‑Cl‑KYN)。

Drugs covered by this patent

esketamine-hydrochloride (ESKETAMINE HYDROCHLORIDE)

Patent Metadata

Patent number: CN114007600A
Jurisdiction: CN
Classification: —
Expires: 2022-02-01
Drug substance claim: No
Drug product claim: No
Assignee: Vistagen Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.